Iniparib: Additional Phase II data

Additional data from a single-arm, open-label, U.S. Phase II trial in 40 evaluable patients showed that IV BSI-201 plus gemcitabine and carboplatin produced an ORR of 65%. The most common adverse events were neutropenia, thrombocytopenia, diarrhea and anemia. The trial enrolled 41 patients with epithelial ovarian carcinoma, fallopian tube cancer or primary peritoneal carcinoma. Patients received gemcitabine and carboplatin on days 1 and 8 of each 21-day cycle, plus 5.6 mg/kg BSI-201 on days 1, 4, 8 and 11 of each cycle. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...